Opticyte Develops Breakthrough First Cell O<sub>2</sub> Patient Monitor for Organ Failure
Opticyte has revolutionized patient monitoring with the introduction of the groundbreaking Cell O2 Patient Monitor. This innovative device has been granted breakthrough designation by the U.S. Food and Drug Administration (FDA). By utilizing non-invasive optical spectroscopy technology, the Cell O2 Patient Monitor provides continuous, real-time monitoring of cellular oxygen levels, enabling early detection of low oxygen levels within cells.
The significance of this device lies in its potential to significantly reduce the occurrence of organ failure. During hospital treatment for conditions such as sepsis, trauma, or myocardial infarction, the Cell O2 Patient Monitor offers immediate and continuous tracking of cellular oxygen levels. This capability allows healthcare professionals to promptly identify patients at risk of organ failure and intervene swiftly.
With the introduction of this cutting-edge device, medical practitioners can approach patients who are on the precipice of organ failure due to sepsis, trauma, or cardiac surgery with greater efficiency. Given that sepsis affects a staggering 1.7 million individuals in the United States annually and contributes to approximately 270,000 deaths, the Cell O2 Patient Monitor holds immense promise for improving patient outcomes.
Compared to the current standard of care, which involves the collection of blood samples, laboratory work, and approximately two hours of testing time for patients with sepsis, trauma, or myocardial infarction, among other conditions, the Cell O2 Patient Monitor represents a remarkable advancement. This device eliminates the need for invasive procedures and expedites the process of identifying organ dysfunction, enabling healthcare professionals to take timely and targeted actions to save lives.